The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.
iShares Biotechnology ETF IBB
Morningstar’s Analysis IBB
Will IBB outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.1
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Gilead Sciences Inc | 8.41 | 651.0 Mil | Healthcare |
Amgen Inc | 8.07 | 624.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.96 | 616.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 7.93 | 613.4 Mil | Healthcare |
IQVIA Holdings Inc | 4.01 | 310.1 Mil | Healthcare |
Moderna Inc | 3.78 | 292.3 Mil | Healthcare |
Biogen Inc | 3.10 | 239.8 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 2.82 | 218.4 Mil | Healthcare |
Mettler-Toledo International Inc | 2.76 | 213.8 Mil | Healthcare |
argenx SE ADR | 2.23 | 172.3 Mil | Healthcare |